Related Experiment Video
Updated: Aug 29, 2026
Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
Published on: May 9, 2025
Immunohistochemical determination of HER-2/neu in malignant melanoma
Anil Potti1, Rachel Hille, Michael Koch
1Department of Medicine, Division of Oncology and Department of Internal Medicine, University of North Dakota School of Medicine, Fargo, ND 58102, USA.
Background:
HER-2/neu onco-protein is increasingly being recognized as a target for therapy in solid tumors, but data on its role in malignant melanoma is currently limited. Our study objective was to determine a relationship, if any, between HER-2/neu overexpression and malignant melanoma.
Patients And Methods:
Overexpression of HER-2/neu was evaluated in patients with malignant melanoma by using immunchistochemistry (DAKO Hercep test) in 202 archival tissue specimens.
Results:
Between 1991 and 2001, 202 subjects [109 males; (54%) and 93 females; (46%)] with malignant melanoma were studied. Interestingly, only 2 of the 202 patients (0.9%) with biopsy-proven malignant melanoma revealed HER-2/neu overexpression.
Conclusion:
The results of our large study indicate that the HER-2/neu onco-protein neither has a role in melanogenesis nor is a potential target for clinical trials with monoclonal antibody therapy. Thus, there is no role for HER-2/neu testing in patients with malignant melanoma.
More Related Videos
07:41A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
10:21Protocol for HER2 FISH Using a Non-cross-linking, Formalin-free Tissue Fixative to Combine Advantages of Cryo-preservation and Formalin Fixation
Published on: December 25, 2017